These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
112 related items for PubMed ID: 7581115
1. High-dose cyclosporine and corticosteroids for prophylaxis of acute and chronic graft-versus-host disease. Schwinghammer TL, Bloom EJ, Rosenfeld CS, Wilson JW, Przepiorka D, Shadduck RK. Bone Marrow Transplant; 1995 Jul; 16(1):147-54. PubMed ID: 7581115 [Abstract] [Full Text] [Related]
2. GVHD prophylaxis using low-dose cyclosporine improves survival in leukaemic recipients of HLA-identical sibling transplants. Olsson R, Remberger M, Hassan Z, Omazic B, Mattsson J, Ringdén O. Eur J Haematol; 2010 Apr; 84(4):323-31. PubMed ID: 20002156 [Abstract] [Full Text] [Related]
5. Impact of cyclosporine and methylprednisolone dose used for prophylaxis and therapy of graft-versus-host disease on survival and relapse after allogeneic bone marrow transplantation. Michallet M, Perrin MC, Belhabri A, Molina L, Nicolini F, Tigaud JD, Sotto JJ, Guyotat D, Fière D, Archimbaud E. Bone Marrow Transplant; 1999 Jan; 23(2):145-50. PubMed ID: 10197799 [Abstract] [Full Text] [Related]
7. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft. Herrera C, Torres A, García-Castellano JM, Roman J, Martin C, Serrano J, Falcon M, Alvarez MA, Gomez P, Martinez F. Bone Marrow Transplant; 1999 Mar; 23(5):443-50. PubMed ID: 10100557 [Abstract] [Full Text] [Related]
8. Prognostic factors for long-term survival in leukemic marrow recipients with special emphasis on age and prophylaxis for graft-versus-host disease. Aschan J, Ringdén O. Clin Transplant; 1994 Jun; 8(3 Pt 1):258-70. PubMed ID: 8061365 [Abstract] [Full Text] [Related]
9. The outcome of unrelated donor bone marrow transplantation in patients with hematologic malignancies using tacrolimus (FK506) and low dose methotrexate for graft-versus-host disease prophylaxis. Devine SM, Geller RB, Lin LB, Dix SP, Holland HK, Maurer D, O'Toole K, Keller J, Connaghan DG, Heffner LT, Hillyer CD, Rodey GE, Winton EF, Maher RM, Fitzsimmons WE, Wingard JR. Biol Blood Marrow Transplant; 1997 Apr; 3(1):25-33. PubMed ID: 9209738 [Abstract] [Full Text] [Related]
11. Do corticosteroids add any benefit to standard GVHD prophylaxis in allogeneic BMT? Ancín I, Ferrá C, Gallardo D, Peris J, Berlanga J, Gonzalez JR, Virgili N, Grañena A. Bone Marrow Transplant; 2001 Jul; 28(1):39-45. PubMed ID: 11498742 [Abstract] [Full Text] [Related]
12. Continuous infusion cyclosporine and nifedipine to day +100 with short methotrexate and steroids as GVHD prophylaxis in unrelated donor transplants. Liesveld J, Duerst R, Rapoport A, Constine L, Abboud C, Packman C, Wedow L, Zwetsch L, McKenna B, Linder T, Silverman W, Swift S, Rowe J, DiPersio J. Bone Marrow Transplant; 1999 Sep; 24(5):511-6. PubMed ID: 10482935 [Abstract] [Full Text] [Related]
13. Cyclosporin, methotrexate and prednisolone for graft-versus-host disease prophylaxis in allogeneic peripheral blood progenitor cell transplants. Hoyt R, Ritchie DS, Roberts AW, Macgregor L, Curtis DJ, Szer J, Grigg AP. Bone Marrow Transplant; 2008 Apr; 41(7):651-8. PubMed ID: 18176619 [Abstract] [Full Text] [Related]
14. Cyclosporin A and mini short-term methotrexate vs cyclosporin A as graft-versus-host disease prophylaxis in patients with beta thalassemia major undergoing allogeneic blood and marrow transplantation. Iravani M, Mousavi A, Gholibeikian S, Bahar B, Samiee S, Ashouri A, Eghbal L, Ghavamzadeh A. Bone Marrow Transplant; 2005 Jun; 35(11):1095-9. PubMed ID: 15821773 [Abstract] [Full Text] [Related]
15. Microangiopathy following allogeneic marrow transplantation. Association with cyclosporine and methylprednisolone for graft-versus-host disease prophylaxis. Kalhs P, Brugger S, Schwarzinger I, Greinix HT, Keil F, Kyrle PA, Knöbl P, Schneider B, Höcker P, Linkesch W. Transplantation; 1995 Nov 15; 60(9):949-57. PubMed ID: 7491699 [Abstract] [Full Text] [Related]
16. Addition of low-dose folinic acid to a methotrexate/cyclosporin A regimen for prevention of acute graft-versus-host disease. Russell JA, Woodman RC, Poon MC, Jones AR, Ruether BA. Bone Marrow Transplant; 1994 Sep 15; 14(3):397-401. PubMed ID: 7994261 [Abstract] [Full Text] [Related]
17. The impact of cyclosporin A on acute graft-versus-host disease after allogeneic bone marrow transplantation in children and adolescents with acute lymphoblastic leukemia. Teuffel O, Schrauder A, Sykora KW, Zimmermann M, Reiter A, Welte K, Schrappe M. Bone Marrow Transplant; 2005 Jul 15; 36(2):145-50. PubMed ID: 15908976 [Abstract] [Full Text] [Related]
19. Decreased incidence of acute graft-versus-host disease by continuous infusion of cyclosporine with a higher target blood level. Oshima K, Kanda Y, Nakasone H, Arai S, Nishimoto N, Sato H, Watanabe T, Hosoya N, Izutsu K, Asai T, Hangaishi A, Motokura T, Chiba S, Kurokawa M. Am J Hematol; 2008 Mar 15; 83(3):226-32. PubMed ID: 17918253 [Abstract] [Full Text] [Related]
20. Methotrexate vs Cyclosporin A as a single agent for graft-versus-host disease prophylaxis in pediatric patients with hematological malignancies undergoing allogeneic bone marrow transplantation from HLA-identical siblings: a single-center analysis in Japan. Koga Y, Nagatoshi Y, Kawano Y, Okamura J. Bone Marrow Transplant; 2003 Jul 15; 32(2):171-6. PubMed ID: 12838282 [Abstract] [Full Text] [Related] Page: [Next] [New Search]